Back to results
US 2023/0407285 A1Published application
Pcsk9 inhibitors and methods of use thereof
AssigneeAstraZeneca AB
InventorsMichael H. Serrano-Wu, Brian K. Hubbard, Virendar Kaushik, Doug Daniels
Life of this patent
Estimating the term…
Abstract
The invention relates to a novel inhibitor pharmacophore of PCSK9 and heteroaryl compounds that bind the PCSK9 protein.
Claims30
A compound or pharmaceutically acceptable salt thereof, wherein the compound contacts PCSK9 and binds to a binding pocket defined by amino acid residues Val589 and Ser636 of human PCSK9.
-5. (canceled)
-72. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.